Pfizer CEO (Chief Executive Officer) Albert Bourla said on Saturday he had tested positive for COVID-19.
“I’m feeling well and symptom free,” Pfizer CEO Bourla said in a statement.
Bourla, 60, back in August had contacted COVID and had started a course of the company’s oral COVID-19 antiviral treatment, Paxlovid.
Paxlovid is an antiviral medication that is used to treat high-risk people, such as older patients.
Bourla has received four doses of the COVID vaccine developed by Pfizer and its German partner BioNTech.
The chief executive said he has not yet taken the new bivalent booster.
Developed by Moderna and the team of Pfizer and BioNTech, the new so-called bivalent shots aim to tackle the BA.5 and BA.4 Omicron subvariants, which make up 84.8% and 1.8%, respectively, of all circulating variants in the United States, based on latest data.
“I’ve not had the new bivalent booster yet, as I was following CDC guidelines to wait three months since my previous COVID case which was back in mid-August,” Bourla added.
In August, the FDA authorized Pfizer and Moderna’s updated booster shots that target the dominant BA.4 and BA.5 Omicron subvariants.
A federal health agency said this week that over 25 million doses of the so-called bivalent shots had been sent out. That consisted of mostly the Pfizer/BioNTech vaccine, as production of the Moderna vaccine ramps up.
Gold prices extended their decline in Pakistan for the third straight session on Tuesday, in…
The Rupee on Tuesday gained 08 paisa against the US dollar in the interbank trading…
Pakistan earned US $614.947 million by providing different transport services in various countries during the…
The Board of Directors of Habib Bank Limited, one of the country’s largest commercial banks,…
The State Bank of Pakistan will be closed on May 1, tomorrow, due to a…
The 100-Index of the Pakistan Stock Exchange (PSX) witnessed bearish trend on Tuesday, shedding 592.49…
Leave a Comment